| abstract |
Disclosed is a method for treating diseases in which TNFα activity is detrimental by subcutaneously administering a human antibody, preferably a recombinant human antibody, that specifically binds to human tumor necrosis factor α (hTNFα) every other week. The antibody may optionally be administered with methotrexate. The antibody has high affinity for hTNFα (eg, K d = 10 −8 M or less) and slow hTNFα dissociation off-rate (K off = 10 −3 sec −1 or less), and exhibits hTNFα activity in vitro and in vivo. Neutralize. The antibodies of the present invention are full length antibodies or antigen binding portions thereof. Also encompassed by the present invention are kits containing the pharmaceutical composition and instructions for administration, as well as a prefilled syringe containing the pharmaceutical composition. |